Page 17 - Biocon

Biocon posts 22% fall in Q2 net profit on high R&D expenses, staff costs

The Bengaluru-headquartered company posted 10 per cent growth in consolidated revenue on a y-o-y basis to Rs 1,760 crore in Q2

Strong prospects of Biologics business keep Street positive on Biocon

Even though Q2 performance missed estimates, analysts expect a stronger second half

Sebi levies fine on Biocon employee for violating insider trading norms

Accordingly, Sebi imposed a consolidated fine of Rs 3 lakh on Singh for both the violations -- not obtaining pre-clearance and making delayed disclosures

India has potential to increase Covid testing 10-fold: Kiran Mazumdar-Shaw

India, which in March imposed the largest nationwide lockdown globally in response to the pandemic, was taken by surprise by the surging number of infections when it started removing the restrictions

Forbes India Rich List 2020: Ambani dominance continues; see full list

With a global health crisis raging, listed pharma entrepreneurs fared well while those with interests in real estate suffered

Sales of Biocon's itolizumab surge as phase-4 clinical trials begin

With phase 4 clinical trials now on, the sales may see a further uptick if data supports its use on Covid-19 patients, said experts.

Biocon set for bigger insulin play, aims to reach one in five diabetics

Biocon Biologics CEO says portfolio to form a substantial part of $1 bn revenue target, to roll out insulin Aspart by next year

Pick-up in biosimilar launches driving Biocon's prospects; stock rises 7.8%

As US launch of Insulin addresses a large market, improved visibility for more launches will keep sentiment elevated

Biocon shares up 6% after Co launches insulin glargine in US market

Biocon Biologics India and its partner Mylan NV launched insulin glargine injection under the brand Semglee in the US market.

Biocon-Mylan launch insulin Glargine at lowest price in US market

The commercialisation in the US of the drug, which already has approval in 45 countries, gives a boost to Biocon's ambitious target of $1 billion in sales through its biologics division by FY22

Weekly trading ideas by Religare Broking: Buy Grasim Industries, Biocon

Grasim is witnessing a breakout from the range where it has spent the last two months

Biocon chairperson Kiran Mazumdar-Shaw tests positive for Covid-19

Shaw adds to the list of high-profile people who have been tested positive in Bengaluru in a span of few weeks, including Karnataka chief minister B S Yediyurappa

Stock calls by Sameet Chavan of Angel Broking: Sell Tata Motors, Biocon

One can see a formation of 'Bearish Engulfing' pattern on Tata Motors' daily chart

Tata Capital to pick minority stake in Biocon Biologics for $30 million

Equity infusion part of a larger $200-300 million round the company plans to raise over the next few months as it eyes an IPO

Itolizumab to be a blockbuster opportunity for Biocon: Kiran Mazumdar-Shaw

We felt that this was the drug that would actually have a role to play in dealing with the cytokine storm that is being seen in Covid-19 patients, says Shaw

MARKET WRAP: Sensex trims losses, ends 12 pts down; Nifty closes at 11,194

All that happened in the markets today

Market Ahead, July 24: All you need to know before the opening bell

Today, a total of 71 companies including ITC, Asian Paints, and Ambuja Cements are scheduled to announce their quarterly results

Biocon Q1 pre-tax profit declines 21% to Rs 252.30 crore, revenue up 14%

High R&D spend, low profitability in research services due to Covid-19 pull down net profit

Cheer in Covid times

Here's the backstory of Biocon's Alzumab which has been approved by the CDSCO for the treatment of Covid-19 in India

Sensex ends 269 pts up, Nifty tops 11,200; RIL m-cap crosses Rs 13.5 trn

All that happened in the markets today